MedTrace Logo

Platelet-Rich Plasma for Peyronie's Disease

NCT07117955 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2025-08-14

No results posted yet for this study

Summary

The purpose of this clinical trial is to evaluate the effects of Platelet-Rich Plasma (PRP) intralesional injections in men affected by Peyronie's disease (PD) in the fibrotic phase.

Conditions

  • Peyronies Disease

Interventions

OTHER

Autologous Platelet Rich Plasma

6 mL PRP intralesional injections will be administered. After the injections, participants will be instructed to perform penile stretching exercises daily until the next injection and to continue these exercises after the final injection until the 3-month follow-up.

OTHER

Saline solution

6 mL saline solution intralesional injections will be administered. After the injections, participants will be instructed to perform penile stretching exercises daily until the next injection and to continue these exercises after the final injection until the 3-month follow-up.

Sponsors & Collaborators

  • Herlev Hospital

    lead OTHER

Principal Investigators

  • Mikkel M. Fode, Professor, MD, Ph.d. · Herlev and Gentofte University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-20
Primary Completion
2028-06-01
Completion
2028-09-01

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07117955 on ClinicalTrials.gov